KalVista Pharmaceuticals Inc. recently announced the presentation of new data at the European Academy of Allergy and Clinical Immunology Congress 2025 in Glasgow, United Kingdom. The data focus on the efficacy of sebetralstat for the on-demand treatment of hereditary angioedema $(HAE)$ attacks among patients receiving long-term prophylaxis. The KONFIDENT-S study highlighted the challenges of adherence to long-term prophylaxis and the need for effective on-demand treatments. Results showed that oral sebetralstat provided rapid relief for breakthrough attacks, with a median time to symptom relief of 1.3 hours. These findings were presented at the congress, indicating the potential of sebetralstat as a complementary treatment to existing long-term prophylaxis options. Links to the presentations are available on the KalVista website under Publications.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。